病理生理学
中医药
肠道微生物群
微生物群
疾病
肠道菌群
发病机制
医学
生物
生物信息学
病理
免疫学
替代医学
作者
Zhaozhou Zhang,Liqing Du,Quan-Yu Ji,Howe Liu,Zhenxing Ren,Guang Ji,Zhaoxiang Bian,Ling Zhao
标识
DOI:10.1142/s0192415x24500046
摘要
Liver Stagnation and Spleen Deficiency (LSSD) is a Chinese Medicine (CM) pattern commonly observed in gastrointestinal (GI) diseases, yet its biological nature remains unknown. This limits the global use of CM medications for treating GI diseases. Recent studies emphasize the role of gut microbiota and their metabolites in the pathogenesis and treatment of LSSD-associated GI diseases. There is increasing evidence supporting that an altered gut microbiome in LSSD patients or animals contributes to GI and extra-intestinal symptoms and affects the effectiveness of CM therapies. The gut microbiota is considered to be an essential component of the biological basis of LSSD. This study aims to provide an overview of existing research findings and gaps for the pathophysiological study of LSSD from the gut microbiota perspective in order to understand the relationship between the CM pattern and disease progression and to optimize CM-based diagnosis, prevention, and therapy.
科研通智能强力驱动
Strongly Powered by AbleSci AI